LGND has been the topic of several other reports. ValuEngine raised shares of Ligand Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, February 1st. HC Wainwright reissued a buy rating and set a $237.00 price objective on shares of Ligand Pharmaceuticals in a report on Wednesday, February 12th. Roth Capital cut their price objective on shares of Ligand Pharmaceuticals from to and set a buy rating on the stock in a report on Monday, February 10th. Finally, Benchmark started coverage on shares of Ligand Pharmaceuticals in a report on Thursday, February 6th. They set a buy rating and a $135.00 price objective on the stock. Two analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Ligand Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $153.17.
Shares of LGND stock opened at $100.73 on Thursday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 3.43, a PEG ratio of 2.98 and a beta of 1.32. The company’s 50 day moving average is $93.55 and its 200 day moving average is $100.31. The company has a quick ratio of 65.66, a current ratio of 66.09 and a debt-to-equity ratio of 0.85. Ligand Pharmaceuticals has a 52-week low of $84.45 and a 52-week high of $130.50.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Thursday, February 6th. The biotechnology company reported $0.71 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.07. The company had revenue of $27.00 million for the quarter, compared to analyst estimates of $25.30 million. Ligand Pharmaceuticals had a net margin of 523.19% and a return on equity of 4.34%. Ligand Pharmaceuticals’s revenue was down 54.7% compared to the same quarter last year. During the same period last year, the company posted $1.70 earnings per share. Analysts anticipate that Ligand Pharmaceuticals will post 2.27 EPS for the current fiscal year.
In other Ligand Pharmaceuticals news, COO Matthew W. Foehr sold 7,225 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $95.84, for a total value of $692,444.00. Following the completion of the sale, the chief operating officer now directly owns 148,833 shares in the company, valued at $14,264,154.72. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.40% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. FSA Wealth Management LLC acquired a new stake in Ligand Pharmaceuticals in the fourth quarter valued at approximately $26,000. Janus Henderson Group PLC boosted its stake in Ligand Pharmaceuticals by 16.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,817,474 shares of the biotechnology company’s stock valued at $189,544,000 after acquiring an additional 251,452 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Ligand Pharmaceuticals by 105.6% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,214 shares of the biotechnology company’s stock worth $232,000 after buying an additional 1,137 shares during the period. Guggenheim Capital LLC lifted its stake in shares of Ligand Pharmaceuticals by 20.7% during the fourth quarter. Guggenheim Capital LLC now owns 26,015 shares of the biotechnology company’s stock worth $2,713,000 after buying an additional 4,453 shares during the period. Finally, Maverick Capital Ltd. acquired a new stake in shares of Ligand Pharmaceuticals during the fourth quarter worth $1,720,000.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Featured Article: Inverted Yield Curve
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.